Compass Therapeutics, Inc.CMPXEarnings & Financial Report
Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)
Compass Pathways, or COMPASS Pathways, is a British pharmaceutical company developing psychedelics as potential medicines. Its main drug candidate, psilocybin (COMP360), is currently in phase 3 clinical trials for treatment-resistant depression. This candidate has received breakthrough therapy status from the U.S. Food and Drug Administration (FDA). It is the most advanced psychedelic drug candidate in development besides Lykos Therapeutics's midomafetamine (MDMA).
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| OrbiMed Advisors LLC | 13.70% | 18.8M | — | 2024-03-22 |
| Adage Capital Partners, L.P. | 7.75% | 9.9M | ▲ +2.09pp | 2024-02-07 |
| FMR LLC | 3.57% | 4.6M | — | 2024-02-09 |
| Blackstone Annex Master Fund L.P. | 2.60% | 3.6M | — | 2024-08-02 |
| S.S. OR | 1.30% | 1.8M | ▼ -4.70pp | 2024-11-14 |
Insider Transactions
Net 90d: +$0 · buys $0 / sells $0Range:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-04-29 | Neil Lerner | Chief Accounting Officer | Grant | 15.0K | $1.89 | $28.4K |
| 2026-04-29 | Jonathan Anderman | General Counsel | Grant | 25.0K | $1.89 | $47.3K |
1–2 of 2